In a previous report, the dual PI3K/mTOR inhibitor, BEZ235, had antitumor activity against HER2+ GC in PDX models by inhibiting HER2 signaling pathways, indicated by pAkt and pS6 inhibition43. Here, MTOR is linked to gastric cancer.